Jove
Visualize
お問い合わせ

関連する概念動画

Pharmacovigilance01:19

Pharmacovigilance

983
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
983
Methods of Documentation VII: EMR01:30

Methods of Documentation VII: EMR

910
Electronic Medical Records (EMRs) primarily center around electronically documenting patients' health information within a single healthcare organization or practice. They contain essential clinical data related to a patient's medical history, diagnoses, medications, treatment plans, lab results, and other pertinent information relevant to the specific encounter or episode of care. EMRs are designed to streamline documentation and workflow processes within individual healthcare...
910
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

124
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
124
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

382
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
382
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response01:15

Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response

123
Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
123
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

5.2K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
5.2K
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー
  1. ホーム
  2. アムロジピンとその組み合わせを処方された人の使用パターンと患者プロフィールを理解するための遡及電子医療記録研究
  1. ホーム
  2. アムロジピンとその組み合わせを処方された人の使用パターンと患者プロフィールを理解するための遡及電子医療記録研究

関連する実験動画

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.7K

アムロジピンとその組み合わせを処方された人の使用パターンと患者プロフィールを理解するための遡及電子医療記録研究

Sunil Lhila1, Arindam Pande2, Rohit Kumar3

  • 1Cardiology, Rabindranath Tagore International Institute of Cardiac Sciences, Kolkata, IND.

Cureus
|September 2, 2025

PubMed で要約を見る

まとめ
この要約は機械生成です。

アムロディピンは高血圧患者で血圧を効果的に低下させ,インド人ではペダル腫の発生率が低い.

キーワード:
アムロジピンカルシウムチャネルブロッカー電子医療記録高血圧ペダルの腫れ

さらに関連する動画

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.8K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.6K

関連する実験動画

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.7K
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.8K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.6K

科学分野:

  • 心臓病科
  • 薬理学について
  • 公衆衛生

背景:

  • 高血圧はライフスタイルの障害で,血圧管理が必要で,アムロジピン (カルシウムチャネル阻害剤) が第一線治療である.
  • 多様な患者集団におけるアムロディピンの有効性と耐容性を理解することは,高血圧管理を最適化するために極めて重要です.

研究 の 目的:

  • 血圧 (BP) の低下におけるアムロディピンまたはその組み合わせの有効性を評価する.
  • アムロジピンの耐容性,特にペダルの腫の発生率を評価する.
  • アムロジピンによる高血圧患者の治療パターンの分析

主な方法:

  • 高血圧患者の電子医療記録 (EMR) を用いた遡及的長期研究.
  • アムロジピン処方薬とその組み合わせに焦点を当てた匿名化されたデータの分析.
  • シストリックBP (SBP) とダイアストリックBP (DBP) の変化とペダルの腫の発生率を含む.

主要な成果:

  • 統計的に有意なSBPとDBPの減少は,アムロディピンまたはその組み合わせ療法で観察されました (p < 0. 001).
  • ペダル腫の発生率は,以前報告された比率より著しく低い0. 91%であった.
  • この研究では,40歳から64歳の参加者の大半が,脂質不全や糖尿病などの共同疾患を患っていた.

結論:

  • アムロジピンとその組み合わせは,著しい血圧低下効果を示しています.
  • アムロジピンは好調で,ペダルの腫れのような副作用の発生率は非常に低い.
  • この結果は,インドの高血圧患者におけるアムロディピンの有効性と安全性のプロフィールを裏付けています.